Fig. 6.

Abscopal effect after intratumoral ISF35 with anti-CTLA-4 and anti-PD-1 antibody blockade. a Treatment strategy. b Growth of injected and distant, uninjected B16.F10 tumors (n = 5–7). c Mouse survival (n = 5–7). d Tumor antigen (p15E)-specific IFN-γ producing CD8 T cells in circulation (n = 5). e Expression of CD40L on immune cells and tumor cells in treated and untreated tumor after 24 h of ISF35 treatment (n = 3). Data are representative of at least two independent experiments and analyzed by unpaired two-tailed t test or one-way ANOVA. *P < 0.05, **P < 0.005 and ***P < 0.0005. Error bars are SEM. Survival analysis was performed with the log-rank test